Genprex (GNPX) vs Valion Bio (VBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Genprex is the larger company by market cap ($2.3 million vs $2.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNPX | VBIO |
|---|---|---|
| Share price | $2.75 | $2.21 |
| Market cap | $2.25M | $1.96M |
| 1-day change | +4.96% | +0.91% |
| EPS (TTM) | $-9.35 | $-177.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1,210.00 | $76.50 |
| 52-week low | $2.53 | $2.05 |
| Distance from 52-week high | -99.77% | -97.11% |
| Average volume | 247.06K | 1.46M |
| Shares outstanding | 819.71K | 887.59K |
| Employees | 13 | 52 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Genprex
GNPX stock →Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Healthcare · Biotechnology · 13 employees
About Valion Bio
VBIO stock →Valion Bio, Inc. operates as a late-stage biopharmaceutical company.
Healthcare · Biotechnology · 52 employees
GNPX vs VBIO FAQ
Which is bigger, Genprex or Valion Bio?
Genprex (GNPX) is larger, with a market capitalization of $2.25M compared with $1.96M for Valion Bio (VBIO).
Are Genprex and Valion Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.